Therapeutics

Tools

Back to the Top
Search By Attributes

Search Results

Name Synonyms FDA Status Company Target Type Therapy Type Approved
For
BIIB076 NI-105,
6C5 huIgG1/l
Alzheimer's Disease (Phase 1) Biogen, Eisai Co., Ltd., Neurimmune Tau Immunotherapy (passive)
Bepranemab UCB0107 ,
UCB 0107 ,
Antibody D
Progressive Supranuclear Palsy (Phase 1), Alzheimer's Disease (Phase 1) Hoffmann-La Roche, UCB S.A. Tau Immunotherapy (passive)
E2814 Alzheimer's Disease (Phase 1) Eisai Co., Ltd. Tau Immunotherapy (passive)
LY3372993 Alzheimer's Disease (Phase 1) Eli Lilly & Co. Amyloid-Related Immunotherapy (passive)
Lu AF87908 Alzheimer's Disease (Phase 1) H. Lundbeck Tau Immunotherapy (passive)
MEDI1814 Alzheimer's Disease (Phase 1) AstraZeneca, Eli Lilly & Co. Amyloid-Related Immunotherapy (passive)
PNT001 Alzheimer's Disease (Phase 1), Traumatic Brain Injury (Phase 1) Pinteon Therapeutics Tau Immunotherapy (passive)
RO7126209 RG6102,
Brain shuttle gantenerumab
Alzheimer's Disease (Phase 1) Hoffmann-La Roche Amyloid-Related Immunotherapy (passive)
SAR228810 Alzheimer's Disease (Phase 1) Sanofi Amyloid-Related Immunotherapy (passive)